Citation

MMWR Morb. Mortal. Wkly. Rep. 2013; 62(3): 56.

Copyright

(Copyright © 2013, (in public domain), Publisher U.S. Centers for Disease Control and Prevention)

DOI

unavailable

PMID

23344700

Abstract

Buprenorphine (Subutex) and buprenorphine/naloxone (Suboxone) received Food and Drug Administration approval in 2002 for the treatment of opioid dependence. Introduction of these drugs expanded the availability of opioid-dependence treatment options to reduce the morbidity and mortality associated with opioid abuse, and buprenorphine has become an increasingly prescribed component of office-based treatment. However, unsupervised ingestion of buprenorphine-containing products by children is a growing concern.

Language: en